Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | PI4KA | P42356 | 3/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | ADA | P00813 | 4/20 | 0.55 |
| ▸ | PDE2A | O00408 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30881556 | 0.98 | ADORA2A (0.96) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24205121 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL18521145 | 0.87 | ADORA2A (0.77) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8955888 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL19779293 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5016844 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4813561 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| Hydrochloric Acid SCHEMBL9193025 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22300665 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL179437 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | ILLUMINA, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4380930-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240141360-A1 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA | MONASH UNIVERSITY (AU) | 2024-05-02 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179116-A1 | Fused Pentacyclic Polyethers | UNIVERSITY OF NORTH CAROLINA AT WILMINGTON | 2007-08-02 | — | — | US | disclosed |
| US-7202271-B2 | Fused pentacyclic polyethers | UNIVERSITY OF NORTH CAROLINA (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202271-B2 | Fused pentacyclic polyethers | UNIVERSITY OF NORTH CAROLINA (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| US-7157441-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA2A 385/4885ADORA1 446/4885PI4KA 2825/4885 |
| US-12030911-B2 | Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA | RNASEH1, RNASE1, DNASE1 | ADORA2A 1751/4885ADORA1 1203/4885PI4KA 553/4885 |
| US-20070179116-A1 | Fused Pentacyclic Polyethers | MUC1, CFTR, CYSLTR1 | ADORA2A 2198/4885ADORA1 376/4885PI4KA 3357/4885 |
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | ADORA2A 3304/4885ADORA1 3504/4885PI4KA 2668/4885 |
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | ADORA2A 131/4885ADORA1 22/4885PI4KA 1389/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | ADORA2A 174/4885ADORA1 283/4885PI4KA 2272/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | ADORA2A 186/4885ADORA1 249/4885PI4KA 2780/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | ADORA2A 81/4885ADORA1 220/4885PI4KA 3965/4885 |
| US-20240209015-A1 | METHODS OF SEQUENCING USING 3' BLOCKED NUCLEOTIDES | RNGTT, NT5C3B, NSUN2 | ADORA2A 67/4885ADORA1 134/4885PI4KA 2323/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | ADORA2A 195/4885ADORA1 343/4885PI4KA 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.